Brief: Equillium Announces Publication Of Data On CD6-ALCAM Pathway
04/01/2022 14:43
Jan 4 (Reuters) - Equillium Inc EQ.O :
* EQUILLIUM ANNOUNCES PUBLICATION OF DATA IN THE JOURNAL OF
CLINICAL INVESTIGATION HIGHLIGHTING THE IMPORTANCE OF THE
CD6-ALCAM PATHWAY IN THE PATHOGENESIS OF LUPUS NEPHRITIS
Source text for Eikon: ID:nBw9Qdtpqa
Further company coverage: EQ.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Equillium
See all newsBrief: Equillium Receives Australian Regulatory Clearance To Initiate First-In-Human Clinical Trial Of Eq504
Equillium Inc reports results for the quarter ended June 30 - Earnings Summary
Equillium Q2 post narrower net loss than expected; starts R&D initiatives
Equillium Inc expected to post a loss of 5 cents a share - Earnings Preview
Equillium Q1 net loss, profit miss analyst expectations